167 related articles for article (PubMed ID: 37108055)
1. Collateral Sensitivity to Fosfomycin of Tobramycin-Resistant Mutants of
Genova R; Laborda P; Cuesta T; Martínez JL; Sanz-García F
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108055
[TBL] [Abstract][Full Text] [Related]
2. Rapid Phenotypic Convergence towards Collateral Sensitivity in Clinical Isolates of Pseudomonas aeruginosa Presenting Different Genomic Backgrounds.
Hernando-Amado S; López-Causapé C; Laborda P; Sanz-García F; Oliver A; Martínez JL
Microbiol Spectr; 2023 Feb; 11(1):e0227622. PubMed ID: 36533961
[TBL] [Abstract][Full Text] [Related]
3. Convergent phenotypic evolution towards fosfomycin collateral sensitivity of Pseudomonas aeruginosa antibiotic-resistant mutants.
Laborda P; Martínez JL; Hernando-Amado S
Microb Biotechnol; 2022 Feb; 15(2):613-629. PubMed ID: 33960651
[TBL] [Abstract][Full Text] [Related]
4. Mutational background influences
Hernando-Amado S; Laborda P; Valverde JR; Martínez JL
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109370119. PubMed ID: 35385351
[TBL] [Abstract][Full Text] [Related]
5. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
McCaughey G; Diamond P; Elborn JS; McKevitt M; Tunney MM
PLoS One; 2013; 8(7):e69763. PubMed ID: 23936095
[TBL] [Abstract][Full Text] [Related]
6. Rapid and robust evolution of collateral sensitivity in
Hernando-Amado S; Sanz-García F; Martínez JL
Sci Adv; 2020 Aug; 6(32):eaba5493. PubMed ID: 32821825
[TBL] [Abstract][Full Text] [Related]
7. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
[No Abstract] [Full Text] [Related]
8. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa.
Takahashi K; Kanno H
Antimicrob Agents Chemother; 1984 Nov; 26(5):789-91. PubMed ID: 6440482
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations.
Díez-Aguilar M; Morosini MI; Tedim AP; Rodríguez I; Aktaş Z; Cantón R
Antimicrob Agents Chemother; 2015 Oct; 59(10):6039-45. PubMed ID: 26195514
[TBL] [Abstract][Full Text] [Related]
11. Tackling antibiotic resistance by inducing transient and robust collateral sensitivity.
Hernando-Amado S; Laborda P; Martínez JL
Nat Commun; 2023 Mar; 14(1):1723. PubMed ID: 36997518
[TBL] [Abstract][Full Text] [Related]
12. Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
McCaughey G; Gilpin DF; Schneiders T; Hoffman LR; McKevitt M; Elborn JS; Tunney MM
Antimicrob Agents Chemother; 2013 Nov; 57(11):5406-14. PubMed ID: 23959314
[TBL] [Abstract][Full Text] [Related]
13. Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.
Anderson GG; Kenney TF; Macleod DL; Henig NR; O'Toole GA
Pathog Dis; 2013 Feb; 67(1):39-45. PubMed ID: 23620118
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
McCaughey G; McKevitt M; Elborn JS; Tunney MM
J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of antibiotic combinations in an experimental sepsis model with Pseudomonas aeruginosa.
Aktas Z; Sonmez N; Oksuz L; Boral O; Issever H; Oncul O
Braz J Microbiol; 2023 Dec; 54(4):2817-2826. PubMed ID: 37828396
[TBL] [Abstract][Full Text] [Related]
16. Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa.
MacLeod DL; Velayudhan J; Kenney TF; Therrien JH; Sutherland JL; Barker LM; Baker WR
Antimicrob Agents Chemother; 2012 Mar; 56(3):1529-38. PubMed ID: 22232284
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
MacLeod DL; Barker LM; Sutherland JL; Moss SC; Gurgel JL; Kenney TF; Burns JL; Baker WR
J Antimicrob Chemother; 2009 Oct; 64(4):829-36. PubMed ID: 19679597
[TBL] [Abstract][Full Text] [Related]
18. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.
Rodríguez-Rojas A; Maciá MD; Couce A; Gómez C; Castañeda-García A; Oliver A; Blázquez J
PLoS One; 2010 Apr; 5(4):e10193. PubMed ID: 20419114
[TBL] [Abstract][Full Text] [Related]
19. The Inactivation of the Putative Two-Component System Sensor PA14_27940 Increases the Susceptibility to Several Antibiotics and Reduces the Motility of
Genova R; Gil-Gil T; Cuesta T; Martínez JL; Sanz-García F
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139182
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
Avery LM; Sutherland CA; Nicolau DP
J Med Microbiol; 2019 Jun; 68(6):893-897. PubMed ID: 31050629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
